Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2021 Filed Jan 3, 2022 15:27 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 21 | $58.40 | $1,226.40 |
DisclosureSEC source: 0001225208-22-000021 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,265 Underlying: Common Stock · 21 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 15:27 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $58.40 | $175.20 |
DisclosureSEC source: 0001225208-22-000022 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,751 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 23:03 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Exercise / conversionStock Appreciation Rights · Derivative | 77,709 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001225208-21-015181 · doc4.xml · derivative · entry 5 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,709 shares Expires 2022-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 23:03 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Exercise / conversionStock Appreciation Rights · Derivative | 153,790 | $0.00 Strike: $27.34 | $0.00 |
DisclosureSEC source: 0001225208-21-015181 · doc4.xml · derivative · entry 4 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153,790 shares Expires 2022-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 23:03 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 42,975 | $25.60 | $1,100,160.00 |
DisclosureSEC source: 0001225208-21-015181 · doc4.xml · nonDerivative · entry 2 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 23:03 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 80,080 | $27.34 | $2,189,387.20 |
DisclosureSEC source: 0001225208-21-015181 · doc4.xml · nonDerivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 23:31 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 152,085 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001225208-21-015184 · doc4.xml · derivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,085 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 23:31 UTC |
Dolsten MikaelPresident R&D
|
OtherPhantom Stock Units · Derivative | 25,219 | $59.48 | $1,500,026.12 |
DisclosureSEC source: 0001225208-21-015184 · doc4.xml · derivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,983 Underlying: Common Stock · 25,219 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · shares: The reporting person diversified shares held in the Pfizer Inc. Deferred Compensation Plan (Plan) pursuant to the Plan's diversification provision into an alternate investment option(s) under the Plan. F4 · derivative.exercise_date: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F4 · derivative.expiration_date: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 23:31 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 71,187 | $30.17 | $2,147,711.79 |
DisclosureSEC source: 0001225208-21-015184 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 23:05 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 8 | $58.80 | $470.40 |
DisclosureSEC source: 0001225208-21-015078 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,865 Underlying: Common Stock · 8 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 23:05 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 21 | $58.80 | $1,234.80 |
DisclosureSEC source: 0001225208-21-015079 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,248 Underlying: Common Stock · 21 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 23:05 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $58.80 | $176.40 |
DisclosureSEC source: 0001225208-21-015080 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 23:05 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 8 | $58.80 | $470.40 |
DisclosureSEC source: 0001225208-21-015081 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,635 Underlying: Common Stock · 8 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 4,727 | $53.39 | $252,374.53 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 11 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,844 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 3,627 | $53.38 | $193,609.26 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 10 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,571 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 2,756 | $53.40 | $147,170.40 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 9 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,198 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 2,719 | $53.50 | $145,466.50 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 8 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,954 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 2,200 | $53.46 | $117,612.00 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 7 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,673 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 1,200 | $53.49 | $64,188.00 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 6 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,873 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 500 | $53.42 | $26,710.00 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,073 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 400 | $53.41 | $21,364.00 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 4 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,573 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 371 | $53.37 | $19,800.27 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,973 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 300 | $53.51 | $16,053.00 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,344 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:18 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 200 | $53.47 | $10,694.00 |
DisclosureSEC source: 0001225208-21-014512 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,644 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 22:18 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 41,360 | $54.26 | $2,244,193.60 |
DisclosureSEC source: 0001225208-21-014513 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,280 Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 21:50 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 9 | $53.73 | $483.57 |
DisclosureSEC source: 0001225208-21-014279 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,887 Underlying: Common Stock · 9 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 21:50 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 23 | $53.73 | $1,235.79 |
DisclosureSEC source: 0001225208-21-014280 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,233 Underlying: Common Stock · 23 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 21:50 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $53.73 | $161.19 |
DisclosureSEC source: 0001225208-21-014281 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,749 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 21:50 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 8 | $53.73 | $429.84 |
DisclosureSEC source: 0001225208-21-014282 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,645 Underlying: Common Stock · 8 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 20,520 | $54.44 | $1,117,108.80 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 14 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,575 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 12,370 | $54.64 | $675,896.80 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 13 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,095 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 3,700 | $54.55 | $201,835.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 12 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,465 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 2,279 | $54.45 | $124,091.55 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 11 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,165 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 1,130 | $54.65 | $61,754.50 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 10 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,444 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 901 | $54.56 | $49,158.56 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 9 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,574 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 800 | $54.47 | $43,576.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 8 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,475 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 700 | $54.49 | $38,143.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,275 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 700 | $54.50 | $38,150.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,975 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 400 | $54.51 | $21,804.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,675 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 399 | $54.53 | $21,757.47 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 4 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,075 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 250 | $54.57 | $13,642.50 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,474 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 101 | $54.48 | $5,502.48 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,724 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 58 | $54.43 | $3,156.94 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,825 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 6,400 | $54.30 | $347,520.00 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 12 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,317 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 5,856 | $54.31 | $318,039.36 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 11 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,717 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 5,765 | $54.40 | $313,616.00 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 10 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,573 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 5,203 | $54.17 | $281,846.51 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 9 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,338 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 4,500 | $54.55 | $245,475.00 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 8 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,541 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 4,200 | $54.50 | $228,900.00 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 7 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,041 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 2,736 | $54.39 | $148,811.04 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 6 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,241 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.